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Poor inhaler technique and nonadherence impair the eﬃcacy of medications for asthma and chronic obstructive pulmonary
disease (COPD). A range of factors, including age, dexterity, inspiratory capacity, cognitive ability, health literacy, and ethnicity,
can impact a patient’s ability and intention to use their device. Treatment success can also be inﬂuenced by patient preferences and
perceptions. +erefore, it is important that healthcare professionals eﬀectively match inhaler devices to individual patients’ needs
and abilities and empower patients by including them in treatment decisions. Physicians must, therefore, fully understand the
characteristics of each device, as well as their patients’ demographic characteristics and comorbidities. Following device selection,
patient training and education, including a physical demonstration of the device, are key to eliminate any critical errors that may
impact on health outcomes. Inhaler technique should be frequently rechecked. +is review will examine the important role of
primary care providers in the selection of appropriate inhaler devices and provision of training for patients with COPD and
asthma to optimize correct inhaler use and adherence. An overview of the key features of available devices and of the factors to
consider when selecting devices will be provided in the context of current asthma and COPD guidelines.
1. Introduction
Asthma and chronic obstructive pulmonary disease (COPD)
are chronic inﬂammatory pulmonary diseases that aﬀected
339 and 252 million people, respectively, worldwide in 2016
[1]. Both disorders cause airﬂow limitation, and inhaled
medications—including inhaled corticosteroids, short- and
long-acting β2 agonists, and antimuscarinic drugs—are
central to their management [2, 3]. Inhaled therapy ensures
rapid and direct delivery to the site of pathology and can be
provided to patients via a range of devices, including neb-
ulizers, pressurized metered-dose inhalers (pMDIs), dry
powder inhalers (DPIs), and soft mist inhalers (SMIs).
Despite the wide availability of these devices, poor inhaler
technique and nonadherence to inhaled therapy has
a marked eﬀect on the therapeutic beneﬁt of medication for
asthma and COPD [4]. Studies consistently report that many
patients with asthma and COPD do not use their inhaler
devices correctly [5, 6]. A recent systematic literature review
and meta-analysis found that incorrect technique is com-
mon across devices, with up to 100% of patients demon-
strating at least one error [5]. Moreover, up to 92% of
patients experience critical errors, that is, one that may
impact the eﬀectiveness of the delivered drug [5]. Indeed,
medications for asthma and COPD cannot be eﬀective if
they do not reach the airways they are intended to target
[7, 8]. Poor inhaler technique stems in part from the fact that
the purpose and how to use inhalation devices are often
poorly understood by patients, which can also lead to a re-
luctance to use the prescribed devices [9]. +e variety of
device types prescribed to patients can cause additional
confusion and further impede eﬀective use [10]. Due to these
various reasons, poor adherence is common, with 50% or
more of patients with asthma and COPD not taking their
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inhaled therapy as prescribed or instructed [11, 12]. Non-
adherence can further perpetuate poor technique and can
lead to costly exacerbations and worsening disease [11, 12].
It has been demonstrated that a shared-care approach
(where patient goals and preferences are accommodated)
and comprehensive patient education, including device
training, can improve outcomes [13, 14]. However, even
with training, not all patients are able to use their inhalers
correctly [15]. For instance, some devices are unsuitable for
use in certain patients (e.g., the patient may have an inability
to hold the device correctly, or their instinctive technique
may not match that of the prescribed device). +erefore,
ensuring a match between patient and device at the outset of
treatment is critical.
In this regard, as a common ﬁrst point of contact and
a prescriber of inhaled medications, the primary care
physician has a vital role in optimizing outcomes for patients
with asthma or COPD by selecting inhaler devices that are
appropriate for individual patients. Furthermore, they are
best placed to encourage the patient to participate in de-
cisions about their treatment, as well as to help in providing
patient education and training.
+is review will examine the important role of primary
care providers in the selection of appropriate inhaler devices
for patients with COPD and asthma, speciﬁcally how
matching the patient’s inhaled therapy closely to his or her
needs can improve inhaler technique and therefore their
adherence to therapy and patient outcomes.
2. The Right Device for the Right Patient
In order to select the device that is most appropriate for
a particular patient, it is important to recognize that a pa-
tient’s ability to use a device may be inﬂuenced by a range of
factors, including age, ethnicity, dexterity, and inspiratory
capacity. Old or young age can be associated with a variety of
elements to consider. +is is pertinent as asthma is the most
common chronic disease among children [16], and the
prevalence of asthma and COPD increases with age [17, 18].
Older age, for example, increases the likelihood of comorbid
conditions that may impact device selection [18, 19].
Physical issues including weakness, impaired dexterity,
declining vision, poor hearing, and low inspiratory rates may
impact on a patient’s ability to use a device [20]. Declining
cognitive function in the elderly can also impair the ability to
master and recall techniques, as can cognitive and mood
disorders, which are common comorbidities for asthma and
COPD [18, 21]. Similarly, inhaler technique in children with
asthma is generally very poor [22]. Despite being taught the
correct technique, inhaler use is diﬃcult for children and
correct inhalation technique can deteriorate over time [23].
Furthermore, a child’s ongoing adherence to inhaled
treatment can also be inﬂuenced by a parent’s participation
in their disease management [24]. Looking more broadly,
health literacy or language barriers may also inﬂuence device
use by impacting a patient’s ability to understand inhaler
instructions [25]. If a patient fails to achieve symptomatic
control due to poor inhaler technique, they may stop using
their inhaler completely [20]. In addition to such
unintentional nonadherence, patients may intentionally re-
fuse to use a device. For example, commitment to inhaled
medication can be aﬀected by perceived social stigma sur-
rounding device use, which has been shown to be an issue for
adolescents [24]. Finally, the factors that contribute to ad-
herence and impact upon successful treatment appear to vary
by ethnic group, requiring further adaptation of approaches
based on a patient’s background [26, 27].
To increase the likelihood of treatment success and
adherence to therapy, it is crucial to match the device to the
patient [25]. Current guidance recommends that “treatment
decisions should [take] into account any patient charac-
teristics or phenotype that predict the patient’s likely re-
sponse to treatment, together with the patient’s preferences
and practical issues” [2] (Figure 1). To do this, practitioners
ﬁrst need to understand the devices that are available to
patients, their key characteristics, and how these might
impact patients’ preference and practice (Table 1).
2.1. Pressurized Metered-Dose Inhalers (pMDIs). Recent in-
novations have enhanced the functionality of pMDIs, which
were the ﬁrst handheld inhalation device to be developed.
However, common to all pMDIs are a pressurized canister of
drug in solution or suspension, a chamber for producing an
Preferred treatment
For symptom control and risk reduction(i)
Patient characteristics or phenotype
Does the patient have any features that predict diﬀerences in their
future risk or treatment response compared with other patients?
(i)
Patient preference
What are the patient's goals, beliefs, and concerns about asthma
and medications?
(i)
Practical issues
Inhaler technique: Can the patient use the inhaler correctly aer
training?
Adherence: How oen is the patient likely to take the medication?
Cost to patient: Can the patient aﬀord the medication?
(i)
(ii)
(iii)
Figure 1: Overview of factors to consider when choosing controller
options for individual patients [2].
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aerosol, and a mouthpiece for inhalation [28]. For use of
ﬁrst-generation, push-activated pMDIs, coordination of
breathing and actuation is required. Poor coordination leads
to reduced drug delivery, suboptimal disease control, and
increased inhaler use. +e recent CRITical Inhaler mistaKes
and Asthma controL (CRITIKAL) study, which analyzed
inhaler errors in 3660 patients who were using DPIs and
pMDIs found that poor coordination (actuation before
inhalation) was common in users of pMDIs (made by ap-
proximately a quarter of patients) and was associated with
uncontrolled asthma [6]. Issues with poor coordination can
be overcome by employing a spacer or a valved holding
chamber (which allows inhalation over several intakes) [28].
However, these can be bulky, impacting portability [29].
Moreover, as an electrostatic charge can build up and de-
crease output in certain spacers, it has been recommended
that priming doses of drug are used to deposit on the spacer
walls or detergents can be used to coat the walls and reduce
the charge [30, 31]. +ese issues can be mitigated with the
use of nonelectrostatic spacers, such as the AeroChamber®
Plus (Trudell Medical International) or Vortex® (PARI
Respiratory Equipment) [32]. Newer models of MDIs are
breath-actuated, reducing the dependency on coordinated
inhalation and actuation [28], and are associated with better
clinical asthma outcomes [33]. However, it is worth noting
that the most frequent error consistently reported among
pMDI users is failure to inhale slowly and deeply, although
this may not signiﬁcantly impact patient outcomes [6, 34].
2.2. Dry Powder Inhalers (DPIs). DPIs deliver medication to
the lungs in the form of a dry powder via the airstream
created when the patient inhales through the device [28].
+ese devices are breath-actuated mitigating the problems
with coordination that can arise with some pMDIs, and thus
many patients ﬁnd them easier to use [20]. However, many
DPIs require a certain rate of inspiratory ﬂow, making them
unsuitable for patients with severe conditions and in certain
emergency situations [20, 28]. +e CRITIKAL study con-
ﬁrmed the importance of inspiratory eﬀort, as insuﬃciently
fast and forceful inhalation was associated with uncontrolled
asthma occurring in roughly one-third of patients using
DPIs [6]. To remove the reliance on inspiratory eﬀort, device
innovation has led to the development of “active,” power-
assisted DPIs that use an energy source to disperse the drug;
however, such devices are more costly [35]. +ere are
a number of diﬀerent types of DPI, with each requiring
diﬀerent techniques for use, and this can lead to confusion
among users if devices are interchanged [20, 28]. +e three
main systems are as follows: capsule-based, where patients
Table 1: Advantages and disadvantages of the main types of inhalers.
Inhaler Advantages Disadvantages
pMDI
(i) Portable and compact (i) Require coordination
(ii) Multidose device (ii) High deposition in mouth and oropharynx
(iii) Metered dose (iii) “Cold Freon” eﬀect
(iv) Established/familiar (iv) Contain propellants
(v) Available for most inhaled medications
pMDI+ spacer
(i) Lower dependency on inspiratory eﬀort (i) Less portable than pMDI
(ii) Easier to coordinate (ii) Certain spacers may acquire electrostatic charge
(iii) Higher lung deposition than pMDI (iii) Additional cost to pMDI
(iv) Reduced mouth and oropharynx deposition (iv) Requires regular maintenance
BA-MDI
(i) Portable and compact (i) Contain propellants
(ii) Multidose device (ii) “Cold Freon” eﬀect
(iii) Breath-actuated (iii) Requires a moderate inspiratory eﬀort
DPI
(i) Portable and compact (i) Requires a minimum inspiratory eﬀort
(ii) Breath-actuated (ii) May not be appropriate for emergency situations
(iii) Does not contain propellants (iii) Multiple designs (may be confusing for the patient)
(iv) Multidose devices available (iv) May be complicated to load
SMI
(i) Portable and compact (i) Not breath-actuated
(ii) Multidose device (ii) Only one device currently available
(iii) Lower dependency on inspiratory eﬀort
(iv) High ﬁne-particle fraction
(v) High lung deposition; low mouth and oropharynx
deposition
(vi) Does not contain propellants
Nebulizers
(i) Can be used at any age (i) Most lack portability
(ii) Can be used by acutely ill (ii) Some require an outside energy source
(iii) No speciﬁc inhalation technique required (iii) Noisy
(iv) Can be used to dispense drugs not available as
pMDI or DPI
(iv) Can result in longer treatment times
(v) Can be expensive
Adapted from [28]. BA-MDI, breath-actuated metered-dose inhaler; DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; SMI, soft mist
inhaler.
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load a capsule containing the powered formulation into the
device before each use; disposable devices containing
a premetered single dose; or multiple-dose inhalers that
either have a built-in mechanism to meter a single dose from
a reservoir with each actuation or that deliver individual
doses from premetered replaceable blisters [36]. For capsule
devices, the patient must continue or repeat inhalation until
the capsule is emptied, which can result in dose variability [36].
2.3. Soft Mist Inhalers (SMIs). +e SMI is the newest type of
device, launched in 2007 when the Respimat® Soft Mist™
Inhaler (Boehringer Ingelheim) successfully gained approval
for use in the European Union.+e device uses spring power
to provide treatment via a slow-moving ﬁne liquid aerosol
[20, 28]. It was designed to produce a higher fraction of ﬁne
and extra-ﬁne particles (deﬁned as 2.1–5 μM and <2.1 μM,
resp. [37]), compared with most pMDIs and DPIs as well as
to provide increased ﬂexibility for synchronization between
actuation and inhalation through the slow movement of the
mist generated [38, 39]. Regional lung deposition varies
according to the aerosol particle size, with particles of
2–6 μM preferentially depositing in the central airways and
those <2 μM in the small airways and alveoli [37]. +erefore,
the SMI results in higher lung (including smaller airways)
and reduced oropharynx drug deposition compared with
other device types [38, 39]. As the energy required to
generate the aerosol is mechanical, and the softer longer
lasting plume moves at a lower velocity compared with
pMDIs, the inhalation eﬀort to operate the SMI is lower.
2.4.Nebulizers. Nebulizers can be used in patients for whom
handheld devices are unsuitable, including the very young,
the elderly, and the acutely ill [20, 40]. +ey require com-
fortable tidal breathing and little coordination from the
patient. However, they can be noisy, and some require an
outside energy source [40]. Generally, they lack portability,
require regular maintenance, are expensive, and result in
longer treatment times [20]. However, new nebulizers have
recently been developed to overcome some of these disad-
vantages, for example, the handheld Aeroneb® Go (Philips
Healthcare), which is portable, compact, and silent [41].
2.5. Considerations for Device Selection. +e diﬀerent in-
halation techniques required for the diﬀerent available de-
vices and inspiratory abilities, as well as patient dexterity and
cognition, form the key considerations when selecting
a device (Figure 2). To aid selection, the use of training
devices/inspiratory ﬂow meters (such as AIM™ (Aerosol
Inhalation Monitor), In-Check DIAL, and 2-Tone trainer)
can be used to assess the patient’s inhalation technique and
inspiratory ability, either when ﬁrst prescribing a new device
to a patient or during regular training and monitoring of
inhaler use [34, 42]. However, an inspiratory ﬂow assess-
ment may not always be reﬂective of a patient’s inspiratory
ability in a real-world setting, and observation of instinctive
inhaler technique can also indicate the type of inhaler that
will be best suited to the patient. Moreover, some prescribed
inhalation devices can indicate whether a patient is using
them appropriately and has the required inspiratory capacity
(e.g., Duaklir Genuair® (AstraZeneca UK Ltd.), where
a control window changes to red from green when the
patient has inhaled correctly), aiding both device choice and
patient technique.
Current guidelines recommend that device selection
should be made in consultation with the patient, who must
be trained in inhaler device technique [2, 3]. Asthma and
COPD treatment guidelines also state that inhaler technique
must be regularly assessed during follow-up consultations
[2, 3]. Moreover, the prescription of mixed inhalation device
types should be avoided to prevent confusion [2]. A large
Patient
Conscious inhalation
possible
Conscious inhalation
not possible
Suﬃcient
inspiratory ﬂow
Insuﬃcient
inspiratory ﬂow
Hand-breath
coordination+
Hand-breath
coordination–
Hand-breath
coordination+
Hand-breath
coordination–
pMDI + holding
chamber
DPI
BA-pMDI
SMI
pMDI
DPI
BA-pMDI
SMI
pMDI ± holding
chamber
BA-pMDI
SMI
pMDI + holding
chamber
BA-pMDI
SMI
Nebulizer
pMDI + holding
chamber
Nebulizer
Figure 2: Device selection algorithm. Reproduced with permission from [28]. DPI, dry powder inhaler; pMDI, pressurized metered-dose
inhaler; BA, breath-actuated; SMI, soft mist inhaler.
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retrospective observational study of patients with asthma in
primary care demonstrated that over one year after a ﬁrst
inhaled corticosteroid prescription, patients prescribed the
same device type for both controller and reliever therapy
were signiﬁcantly more likely to achieve asthma control and
recorded signiﬁcantly lower exacerbation rates than those
prescribed mixed devices [43]. Indeed, several studies have
shown that simultaneous use of diﬀerent inhaler types is
predictive of increased inhalation errors [10]. In addition,
asking patients to switch devices can impact adherence to
therapy. In a retrospective observational study of patients
with COPD, multiple-inhaler users demonstrated lower
adherence rates than single-inhaler users and were signiﬁ-
cantly more likely to discontinue therapy [44].
3. Patient Perceptions and Shared Decisions
Patients have their own perceptions or preferences regarding
inhaler choice, and these can inﬂuence treatment success
[28]. Device features such as simplicity, convenience, and
overall experience are important to patients [28]. Patients
have reported spontaneously ceasing inhaled therapy due to
perceived complexity and are likely to value device features
associated with convenience such as ease of cleaning,
comfort, and portability [28]. Beliefs surrounding treatment—
for example, whether it will be ineﬀective, cause side eﬀects, or
should only be taken when “really needed”—may also aﬀect
a patient’s willingness to adhere to therapy, asmight issues with
device use, such as taste and eﬀect on the throat [28]. By
including the patient in treatment decisions, it is possible to
tailor device selection around such perceptions and prefer-
ences, as well as gaining an understanding of the patient’s
approach to treatment. Even if a diﬀerent device seems to be
a better match for the patient, it may be that they are reluctant
to try a new device because they have become used to their
existing inhaler. +ey may also be apprehensive when
switching devices due to the requirement to acquire new skills
[28]. Others will be encouraged by changing device if they are
having a poor experience with current treatment. Indeed, lack
of perceived beneﬁt has been reported as leading patients to
intentionally discontinue their therapy [45]. In either case,
shared decision-making can empower the patient, and it has
been shown to improve both adherence and health outcomes
[13]. In a randomized controlled trial where clinicians and
patients negotiated a treatment plan that accommodated
patient goals and preferences, shared decision-making was
associated with a higher cumulative dose of medication over
a one-year period, a higher likelihood of well-controlled
asthma, and better lung function [13]. It is therefore im-
portant that patients are encouraged to participate in
treatment decisions and to express their expectations and
concerns [2, 3].
4. Common Errors and Patient Education
Patient errors with inhaler technique are common and have
been linked with poor outcomes in asthma and COPD
[6, 9, 12]. +e CRITIKAL study highlighted that errors
relating to inspiratory eﬀort were frequent in patients using
DPIs and MDIs [6]. Inhalation was insuﬃciently fast and
forceful in up to 38% of individuals using DPIs and was not
slow or deep enough in 47% of patients using MDIs [6].
Errors common with both device types included not having
the head tilted with chin up during inhalation and not
breathing out to empty lungs before inhalation [6]. Many
inhaler errors were associated with asthma symptom con-
trol; for example, insuﬃcient inspiratory eﬀort occurred
frequently and was signiﬁcantly associated with an increased
likelihood of uncontrolled asthma in patients using DPIs [6].
For patients usingMDIs, errors relating to device knowledge
and second dose preparation were associated with un-
controlled asthma, as was actuation before inhalation [6]. A
systematic review of inhaler use, covering 59,584 observed
tests of technique, found that the overall prevalence of
correct technique was 31% and that inhaler technique has
not improved in 40 years [46].
Such studies emphasize the need for new approaches to
patient education and training. A recent systematic review of
educational inhalation technique interventions found that
over 90% of studies included reported a signiﬁcant im-
provement in inhaler technique after an educational in-
tervention (although average follow-up time was short) [47].
Interventions in outpatient clinics performed best, indicating
the importance of primary care providers [47]. +e “teach-
back” technique—where patients demonstrate their inhaler
use after instruction—has been shown to be particularly
beneﬁcial [48]. As well as providing an eﬀective initial edu-
cational intervention, continued support is vital [49, 50].
Indeed, the Global Initiative for Asthma (GINA) strategy
advises that clinicians recheck inhaler technique frequently, as
errors often recur within 4–6 weeks after initial training [2].
+e primary care physician is best placed to address
patients’ perceptions and attitudes towards therapy, to in-
dividualize treatment choice, and to provide tailored edu-
cation and device training to maximize adherence to
treatment. It is also important that pharmacists are familiar
with the device technique, as they are usually the last (and
sometimes the most frequent) healthcare professional to be
seen by patients before a device is used. Studies have
demonstrated that they can provide eﬀective skills training
positively impacting disease control [50, 51]. As such, they
play an important role in reinforcing inhaler technique and
primary care physicians can recommend that their patients
also ask their pharmacists any questions about device
handling, especially when supplied with their own inhaler
and a check-correct-conﬁrm cycle can be conducted [50, 52].
While patient education is often eﬀective, it is critical to
remember that some patient groups will be unable to use
certain devices despite receiving adequate training [21, 53],
thereby reinforcing the importance of ﬁrst matching the
patient with the optimum device. Finally, it is essential that
the selected device reaches the patient. While it is not
commonplace in many countries, it should be stated that
pharmacists should not amend device prescriptions and the
switching of inhaler devices without an accompanying
practitioner consultation should be avoided.
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5. Case Study
(i) A 68-year-old woman who had been prescribed
a tiotropium bromide, HandiHaler®, presents to her
doctor with dyspnea. She was adherent to her
medication, and cardiac etiologies were ruled out.
Her spirometry showed GOLD stage 3 disease with
a forced expiratory volume in 1 second (FEV1) of
48%.
(ii) It was decided to step up her medication to a long-
acting bronchodilator combination of β2-agonist
(LABA)/muscarinic antagonist (LAMA), in the
form of formoterol/aclidinium (Duaklir Genuair)
administered twice a day. She was adherent, but her
condition deteriorated. She felt depressed as her
health worsened despite her medication change.
(iii) We reviewed her inhaler technique. She was using
the device upside down, which was corrected. She
was also reminded of the twice-daily dosing, which
she occasionally forgot.
(iv) A repeat visit showed that the color window did not
turn from green to red after actuation, indicating
that she had insuﬃcient inspiratory ﬂow to activate
it. She was converted to tiotropium/olodaterol,
a Respimat device administered once daily. She
had some diﬃculty loading the canister due to hand
osteoarthritis, and the pharmacist agreed to load her
medication for her on dispensing.
(v) She took two inhalations once daily each morning
and was amazed at how much better she felt.
Her exercise tolerance increased, and her mood
improved.
6. Future Considerations
Primary care physicians have a key role to play in maxi-
mizing inhaled therapy adherence in asthma and COPD by
ensuring that the patient is using a suitable inhaler device,
and can learn and maintain inhaler technique. +is requires
an holistic approach to treatment optimization. Physicians
are required to have a full understanding of the charac-
teristics of each device, in addition to knowledge of their
patient’s physical and cognitive abilities. Moreover, physi-
cians should understand cultural beliefs and perceptions
around treatment, which may impact on adherence. +e
GINA guidelines outline strategies to ensure eﬀective use of
inhaler devices, which should serve as a basis for all primary
care physicians prescribing these (Table 2). Essentially, they
advocate four Cs, summarized below:
(i) Choose: choose the most appropriate inhaler device
for the patient before prescribing
(ii) Check: check inhaler device technique at every
opportunity, including asking the patient to dem-
onstrate their inhaler
(iii) Correct: show the patient how to use the device
correctly via a physical demonstration and recheck
technique frequently
(iv) Conﬁrm: clinicians should be able to demonstrate
correct inhaler technique. Skills training can be
reinforced by pharmacists and nurses.
While algorithms are available to aid device choice [54],
these tend to focus on inspiratory ability and basic physical
traits. Practitioners should be aware that their use will need
to be supplemented with an in-depth understanding of
adherence and technique behaviors in key patient sub-
groups. Furthermore, it is evident that many healthcare
professionals are themselves unable to demonstrate correct
inhaler technique [55]. Given that the most eﬀective patient
training technique in correct inhaler use relies upon physical
demonstration [49], priority must be given to providing
eﬀective training for healthcare professionals to enable them
to eﬀectively educate their patients. Integral to training for
healthcare professionals should be an awareness of common
Table 2: Strategies to ensure eﬀective use of inhaler devices [2].
Choose
(i) Choose the most appropriate inhaler device for the patient before prescribing. Consider the medication options, the available devices,
patient skills, and cost
(ii) If diﬀerent options are available, encourage the patient to participate in the choice
(iii) For pMDIs, use of a spacer improves delivery and (with ICS) reduces the potential for side eﬀects
(iv) Ensure that there are no physical barriers, for example, arthritis, that limit the use of the inhaler
(v) Avoid use of multiple diﬀerent inhaler types where possible, to avoid confusion
Check
(vi) Check inhaler technique at every opportunity
(vii) Ask the patient to show you how they use their inhaler (do not just ask if they know how to use it)
(viii) Identify any errors using a device-speciﬁc checklist
Correct
(ix) Show the patient how to use the device correctly with a physical demonstration, for example, using a placebo inhaler
(x) Check technique again, paying attention to problematic steps. You may need to repeat this process 2-3 times
(xi) Only consider an alternative device if the patient cannot use the inhaler correctly after several repeats of training
(xii) Recheck inhaler technique frequently. After initial training, errors often recur within 4–6 weeks
Conﬁrm
(xiii) Clinicians should be able to demonstrate correct technique for each of the inhalers they prescribe
(xiv) Pharmacists and nurses can provide highly eﬀective inhaler skills training
Reproduced with permission from [2]. pMDI, pressurized metered-dose inhaler; ICS, inhaled corticosteroids.
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mistakes and reasons for nonadherence, which can serve as
a checklist in the provision of patient education [14]. It is
also important to note that inhaler design is an advancing
ﬁeld. Devices are undoubtedly going to become “smarter,”
providing feedback to the patient on adherence and tech-
nique. However, as outlined in a recent editorial com-
menting on a study by Sulaiman et al. [56], the authors
highlighted that while biofeedback devices may improve
adherence and, therefore, disease control, there is a relatively
small impact [57]. Education and structured health plans
remain hugely important, as will keeping up-to-date with
training as these new devices become available [35].
7. Conclusions
Inhaled therapies are the cornerstone of asthma and COPD
management. It is therefore vital that inhaler devices are
prescribed that patients can and will use. Treatment de-
cisions should be made in partnership with patients, and
should take into consideration demographic characteristics
and comorbidities to allow device choice to be in-
dividualized. As asthma and COPD control is suboptimal,
due to patient errors with inhaler technique, common errors
may serve as a checklist for physicians to aid inhaler
technique training. Ultimately, healthcare providers who
work with patients who use inhaled medications have an
essential role in minimizing common patient errors and are
therefore required to “choose, check, correct, and conﬁrm”
to ensure eﬀective use of inhaler devices among their
patients.
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